BACKGROUND: Studies have proposed using the leg lateral reach test (LLRT). However, they did not establish a cut-off point for testing. OBJECTIVE: To establish a cut-off point for the ...
Introduction Kinesiophobia is a significant factor which influences the prognosis of patients with chronic non-specific low back pain (CNLBP). The restriction of functional training can severely ...
JOURNAVX met the primary endpoint by demonstrating statistically significant superior reduction in pain vs placebo. 1,b JOURNAVX did not meet the first key secondary endpoint that hypothesized ...
A personalized protocol involving self-managed cognitive functional therapy (CFT) was associated with sustained symptom improvement at 3 years in patients with chronic low back pain in a phase 3 ...
Please provide your email address to receive an email when new articles are posted on . 86.9% of patients saw a 50% or greater reduction in pain scores from day 1 to day 3. The addition of antiseizure ...
Pain assessment on a numerical scale with uncertainty intervals: a proof-of-concept simulation study
1 Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland 2 Department of BioMedical Research, University of Bern, Bern, ...
BALTIMORE--(BUSINESS WIRE)--ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced it has ...
Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain, sickle cell disease, beta thalassemia, and type 1 diabetes, with approved products in each area. Suzetrigine ...
The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe ...
A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative intended ...
Credit: Vertex The active ingredient in Journavx is suzetrigine, a sodium channel blocker. The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results